Abstract
Sensitivity is a key measure of lateral-flow antigen test (AT) performance, typically compared against qRT-PCR as the gold standard. For COVID-19, diagnostic sensitivity assesses the ability of ATs to detect SARS-CoV-2 nucleoprotein. However, sensitivity estimates can be strongly skewed by variations of the target concentrations within the clinical sample sets. Independent studies evaluating ATs from different manufacturers often display disparate target concentration distributions, making it difficult to compare sensitivity across products. We propose a new methodology to enhance the accuracy of sensitivity calculations, ensuring more reliable comparisons across ATs. Sensitivity is estimated by modeling the probability of positive agreement (PPA) as a function of qRT-PCR cycle thresholds (Cts) via logistic regression of antigen test results. Raw sensitivity is calculated as the ratio of antigen test positives to total PCR positives. Adjusted sensitivity is derived by applying the PPA function to a reference concentration distribution, enabling uniform sensitivity comparisons across tests. This approach minimizes the impact of uneven sampling and external factors, as demonstrated using clinical data from a study in Chelsea, Massachusetts, USA. Over two years, paired antigen and PCR positive tests from four AT suppliers were analyzed: A (211 tests), B (156), C (85), and D (43). The qRT-PCR Ct distributions varied, with suppliers A and D having more high viral load samples, while supplier C had more low viral load samples, causing significant discrepancies in raw sensitivity. Using the PPA function estimated from each supplier's dataset, we calculated the corresponding adjusted sensitivities for common reference Ct distributions, highlighting how sample heterogeneity impacts raw sensitivity. Our approach successfully mitigates this variability, allowing for more accurate sensitivity comparisons. This study demonstrates that sensitivity estimates from real-world data are susceptible to deviations caused by external factors, particularly the heterogeneity of qRT-PCR Ct distributions across studies. We present data supporting a novel methodology that adjusts for this variability by calculating the PPA function from raw data and determining the expected sensitivity based on a reference distribution of qRT-PCR Cts, allowing for more consistent and accurate sensitivity assessments.
Competing Interest Statement
Irene Bosch is a founder of IDX20, a company affiliated with this study. Miguel Bosch is a founder of Info Analytics Innovations, a company also affiliated with this study. The authors declare no additional conflicts of interest.
Funding Statement
This research was supported by Reagan-Udall Foundation through Grant #02282022 RUF and by the NIH Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) program, Grant # R0502A, both awarded to IDX20.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Advarra gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data is available at the Rapid Acceleration of Diagnostics - Underserved Populations (RADxUP, a program funded by the National Institutes of Health (NIH), under the repository conditions.